AiCure

Sandoz

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »


Report: Biosimilars could create $44B in healthcare savings

Wednesday, November 5, 2014 12:52 PM

Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the U.S. by $44 billion over the next decade, according to a new analysis from RAND, a Boston, Mass.-based nonprofit research organization that develops solutions to public policy challenges.

More... »


Cinven to invest in Medpace

Monday, February 24, 2014 12:40 PM

European private equity firm Cinven has announced a majority investment in Medpace, for $915 million plus certain cash inflows relating to the period of ownership, acquired from CCMP Capital Advisors.

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »

Novartis to acquire Fougera Pharmaceuticals

Friday, May 4, 2012 08:02 AM

Switzerland-based Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals of Melville, N.Y., for $1.5 billion in cash.

More... »

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

FDA approves generic olanzapine injection

Thursday, October 27, 2011 10:40 AM

The FDA has approved INNOPHARMA’s Abbreviated New Drug Application (ANDA) for olanzapine injection (the generic equivalent of ZyprexaR injection).

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs